COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00908908
Recruitment Status : Completed
First Posted : May 27, 2009
Results First Posted : January 27, 2012
Last Update Posted : March 9, 2012
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
The purpose of this study is to determine the metabolism and elimination of carbon-14 labeled eribulin acetate (14C-eribulin) in patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: eribulin Phase 1

Detailed Description:

The study will be conducted in two phases, the initial Study phase to administer the radio-labeled 14C-eribulin and collection of PK samples, and the Extension Phase when the patients will continue to receive non-radio-labeled eribulin. In the initial Study phase, patients will receive a single 2 mg flat dose of 14C-eribulin (approximately 80 to 90 microCuries) administered on Cycle 1 Day 1 as an intravenous (IV) bolus injection or infusion over 2-5 minutes. Following this initial dose, patients will remain in the research unit until Day 8 to complete sample collections of urine, blood and feces for PK analysis and determination of 14C-eribulin concentrations between Days 1 and 8.

On Day 8 patients will be re-assessed and discharged, and return on day 15 for physical exam, adverse event evaluation, and lab tests. The patients will then enter the Extension Phase of the study and continue to receive on-radio-labeled eribulin at a dose of 1.4 mg/m^2 on Days 1 and 8 of every 21 day cycle.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors
Study Start Date : March 2009
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: eribulin
Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
Other Name: E7389

Primary Outcome Measures :
  1. Excretion Balance of Radio-labeled 14C-eribulin: Total Recovery of Radioactive Dose in Urine and Feces. [ Time Frame: 312 hours postdose ]
  2. Pharmacokinetics: AUC (0-t) for Total Radioactivity in Plasma [ Time Frame: Between Days 1 and 8 of Cycle 1 ]
    Area under the plasma concentration-time curve from time zero to last quantifiable plasma concentration measuring total radioactivity exposure.

  3. Pharmacokinetics AUC (0-t) for Eribulin in Plasma [ Time Frame: Between Days 1 and 8 of Cycle 1 ]
    Area under the plasma concentration-time curve from time zero to last quantifiable plasma concentration measuring exposure to eribulin.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Patients must have a histologically or cytologically confirmed advanced solid tumor that has progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy). Patients with measurable tumors according to RECIST are desirable but not essential.
  2. Patients must be aged 18 years or older.
  3. Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1, or 2.
  4. Patients must have adequate renal function as evidenced by serum creatinine ≤135 µM/L (≤1.5 mg/dL) or creatinine clearance >= 40 mL/minute (min).
  5. Patients must have adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x 10^9/L and platelet count >= 100 x 10^9/L.
  6. Patients must have adequate hepatic function as evidenced by bilirubin ≤ 1.5 times the upper limit of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 x ULN (in the case of liver metastases ≤ 5 x ULN), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.
  7. Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or below, except for stable sensory neuropathy ≤ Grade 2 and alopecia.
  8. Patients must be willing and able to comply with the study protocol for the duration of the study.
  9. Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion Criteria:

  1. Patients who have received any of the following treatments within the specified period before treatment start:

    • chemotherapy, radiation, or biological therapy within three weeks
    • hormonal therapy within one week
    • any investigational drug within 4 weeks
    • systemic unconventional or alternative therapies including, but not limited to, herbal remedies within 4 weeks
  2. Have had radiation therapy encompassing > 30% of marrow.
  3. Have received prior treatment with mitomycin C or nitrosourea.
  4. Have had major surgery within 4 weeks before starting study treatment
  5. Patients with pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
  6. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks.
  7. Patients with meningeal carcinomatosis.
  8. Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency, and cannot be changed to heparin-based therapy, are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT) or international normalized ratio (INR) must be closely monitored.
  9. Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Peri-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
  10. Patients with severe/uncontrolled intercurrent illness/infection.
  11. Significant cardiovascular impairment (history of congestive heart failure > New York Heart Association (NYHA) grade II, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia).
  12. Patients with organ allografts requiring immunosuppression.
  13. Patients with known positive HIV status.
  14. Patients with pre-existing neuropathy > Grade 2.
  15. Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.
  16. Patients who participated in a prior eribulin clinical trial, whether or not they received eribulin (E7389).
  17. Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00908908

Layout table for location information
Netherlands Cancer Institute
Amsterdam, Netherlands, 1066 CX
Sponsors and Collaborators
Eisai Inc.
Layout table for investigator information
Study Director: Barbara Koetz, MSc Eisai Limited
Layout table for additonal information
Responsible Party: Eisai Inc. Identifier: NCT00908908    
Other Study ID Numbers: E7389-E044-103
First Posted: May 27, 2009    Key Record Dates
Results First Posted: January 27, 2012
Last Update Posted: March 9, 2012
Last Verified: March 2012
Keywords provided by Eisai Inc.:
Advanced Solid Tumors
Failure of Multiple Prior Chemotherapy Regimens
Additional relevant MeSH terms:
Layout table for MeSH terms